New IVL tech overcomes previous limitations | 3-year SMART data looks at TAVR outcomes | Artivion acquires Endospan for $135M

Ziad Ali, MD, said the new device has completely changed the way he and his colleagues treat patients with calcified coronary artery disease. 

These three-year data represent a major update to one of the more noteworthy TAVR trials in recent memory.

The purchase price could end up being closer to $200 million if certain commercial milestones are met.

Late-breaking data out of EuroPCR focused on 420 patients treated with Boston Scientific's new coronary IVL catheter. Overall, the device was found to be both safe and effective for patients with severe CAD.

Baxdrostat, sold by AstraZeneca under the brand name Baxfendy, is now approved to treat hypertension in combination with other antihypertensive medications.

Vivek Reddy, MD, spoke to Cardiovascular Business about some of the biggest trends in electrophysiology today.

Heart Rhythm 2026 Program Chair DJ Lakkireddy, MD, spoke to Cardiovascular Business during the conference about several key EP trends. 

The Mosaic Neo mitral bioprosthesis can be implanted through sternotomy, minimally invasive cardiac surgery or robotic access. 

Researchers tracked real-world data from 600 TAVR patients, following each one for approximately five years. Survival rates were similar for men and women early on, but then women started experiencing better outcomes after three years.

Consider three AI developments that caught our eye at HealthExec this week. 

Washington-based Providence Health and Services denies the allegations. The lawsuit, filed by the state attorney general, details incidents of noncompliance and retaliation dating back to 2021.